Imfinzi and tremelimumab with chemotherapy demonstrated sustained OS benefit in mNSCLC September 13, 2022
Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant mNSCLC September 13, 2022
Trifluridine/tipiracil + bevacizumab showed a statistically significant OS improvement vs trifluridine/tipiracil alone in Ph 3 trial in mCRC patients September 13, 2022
Positive Initial Ph 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) announced September 13, 2022
Positive data announced from multiple expansion cohorts of Ph 1 trial of fianlimab and Libtayo® (cemiplimab) in advanced melanoma September 13, 2022
Positive early data announced for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced NSCLC September 13, 2022
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable CSCC Published in NEJM September 13, 2022
Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA and PADCEV as Monotherapy in 1L Advanced Urothelial Cancer September 13, 2022
FAILED TRIAL: Ph 2 SELECT trial of vopratelimab + pimivalimab combination vs pimivalimab alone did not meet its primary endpoint of mean tumor change in in TISvopra Biomarker-Selected 2L NSCLC Patients September 7, 2022
Ph 3 CodeBreaK 200 trial of LUMAKRAS® (sotorasib) met its primary endpoint of PFS improvement over SoC chemotherapy in KRAS G12C-Mutated NSCLC September 7, 2022
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer June 14, 2022
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development June 14, 2022
Interim dose-escalation data up to 0.3 mg/kg in Ph 1 clinical of ADG116 in patients with advanced/metastatic solid tumors announced March 30, 2021
